Literature DB >> 6362877

Mitoxantrone versus doxorubicin in advanced breast cancer: a randomized cross-over trial.

J A Neidhart, D Gochnour, R W Roach, J A Steinberg, D Young.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6362877     DOI： 10.1016/0305-7372(83)90021-x

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  10 in total

1.  Pirarubicin (4'-o-tetrahydropyranil-adriamycin) for treatment of advanced breast cancer. A Clinical Phase II study.

Authors:  W Scheithauer; H Samonigg; D Depisch; J Schüller; H Hausmaninger; J Wiegele; C Zielinsky; H Stöger; K Haider; P Preis
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

2.  Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study.

Authors:  H T Mouridsen; M Cornbleet; R Stuart-Harris; I Smith; R Coleman; R Rubens; M McDonald; H Rainer; A van Oosterom; J Smyth
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

3.  First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer.

Authors:  P Periti; G R della Cuna; F Pannuti; T Mazzei; P Preti; A Martoni; E Mini
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

4.  Mitoxantrone as a first-line treatment of advanced breast cancer.

Authors:  K Landys; S Borgstrom; T Andersson; H Noppa
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

5.  A phase II study of mitoxantrone in advanced squamous cell cancer of the head and neck.

Authors:  H Wheeler; R L Woods; J Page; J Levi
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

6.  The effects of doxorubicin and mitoxantrone on wound healing.

Authors:  R Noh; G I Karp; D F Devereux
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  Phase II study of vincristine, mitomycin-C and mitoxantrone in advanced breast cancer: a preliminary report of response and toxicity.

Authors:  T J Perren; G Blackledge; J J Mould; A D Chetiyawardana; M Morrison; A Hancock
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

8.  The effect of mitoxantrone treatment in beagle dogs previously treated with minimally cardiotoxic doses of doxorubicin.

Authors:  P Tham; W Dougherty; M J Iatropoulos; G Gordon; V C James; C Hall; J F Noble
Journal:  Am J Pathol       Date:  1987-07       Impact factor: 4.307

9.  Human central nervous system and plasma pharmacology of mitoxantrone.

Authors:  R M Green; D J Stewart; H Hugenholtz; M T Richard; M Thibault; V Montpetit
Journal:  J Neurooncol       Date:  1988       Impact factor: 4.130

10.  Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer. A Southwest Oncology Group study.

Authors:  J O Atiba; S J Green; H E Hynes; C K Osborne; T P Miller; M Davidner
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.